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uEfficacy of Revascularization for Renal Artery Stenosis Caused by
Fibromuscular Dysplasia: A Systematic Review and Meta-Analysis
Trinquart L, Mounier-Vehier C, Sapoval M, et al. Hypertension 2010;56:
525-32.
Conclusion: Renal artery vascularization in patients with fibromuscu-
lar disease (FMD) by angioplasty or surgery yields moderate benefits, with
significant variation among studies. Blood pressure outcome is strongly
influenced by patient age.
Summary: Surgery and percutaneous renal artery angioplasty are both
used to treat renal artery stenosis. Benefit for revascularization of atheroscle-
rotic renal arteries stenosis is limited (Nordmann AJ, Cochrane Database
Syst Rev 2003:CD002944; Balk E et al, Ann InternMed 2006;145:901-12;
Wheatley K et al, N Engl J Med 2009;361:1953-62). The limited benefit of
revascularization of atherosclerotic renal artery stenosis is thought to reflect
underlying renal parenchymal disease associated with age.However, patients
with FMD are younger (30s and 40s), with normal kidney function. FMD
patients are also primarily women. No randomized control trials and no
comprehensive systematic reviews have assessed blood pressure outcome
with revascularization for renal artery stenosis secondary to FMD. The
primary objective of this systematic review was to assess the rate of hyper-
tension cure after renal artery revascularization in patients with hypertension
and FMD renal artery stenosis. Other objectives were to assess technical
success rates of revascularization, risk of complication, and to explore
variation of outcomes across subgroups. This systematic review includes
studies of both surgical and percutaneous revascularization of FMD renal
artery stenosis.
The authors selected 47 angioplasty studies involving 1660 patients
and 23 surgical studies involving 1014 patients. Using the definition of cure
particular to each study, combined rates of hypertension cure were estimated
to be 46% (95% CI, 40%-52%) after angioplasty and 58% (95% CI, 53%-62%)
after surgery. There was substantial variation across studies. Patient age and
time of publication were negatively associated with the probability of being
“cured.” Cure rates using the current definition of hypertension cure (blood
pressure 140/90 mm Hg, without treatment) were only 36% after angio-
plasty and 54% after surgery, respectively. Risk of periprocedural complica-
tions were 12% after angioplasty and 17% after surgery, with fewer major
complications after angioplasty (6%) vs surgery (15%).
Comment: This is the largest meta-analysis reported on this subject.
Overall, this study found that the probability of cure for revascularization of
renal artery stenosis secondary to FMD was negatively associated with age,
known duration of hypertension, medial-type FMD, time of publication,
and a more strict definition of cure. Future studies of revascularization for
renal artery stenosis should include standardization of the definition of
blood pressure cure using the current criteria of a blood pressure 140/90
mm Hg, without treatment, as the definition of cure. Because only one
patient in three has a normal blood pressure after percutaneous renal artery
revascularization for FMD, with a 12% risk of complications, a randomized
trial comparing percutaneous renal artery angioplasty with medical treat-
ment for FMD should be considered.
Results of Superior Vena Cava Reconstruction With Externally Sup-
ported Polytetrafluorethylene Vascular Prostheses
Okereke IC, Kesler KA, Rieger KM, et al. Ann Thorac Surg 2010;90;383-7.
Conclusion: Superior vena cava (SVC) reconstructions with externally
supported polytetrafluorethylene (PTFE) grafts have low perioperative mor-
tality and high short-term patency.
Summary: SVC obstruction can result in facial swelling, dyspnea, and
stridor. The SVC, depending on individual circumstances, may be recon-
structed with autogenous tissue, stents, or grafts. In this report, the authors
describe experience with SVC reconstruction using externally supported
PTFE grafts. The study spans 1991 to 2002 and was a retrospective review
of medical records of 38 patients with SVC reconstruction with externally
supported PTFE grafts. All but four patients had reconstruction for malig-
nant disease.Mean age was 45 15.8 years, and 77%weremen. The surgical
approach was sternotomy in 27 and thoracotomy in 8, with a clamshell
incision in 3 and a trap-door incision in 1. The technique involved initial
dissection of the tumor or benign surrounding tissue with assessment of the
SVC. The innominate veins and the SVC just proximal to right atrial–SVC
junction were both isolated. The azygous vein was ligated. SVC clamping
was well tolerated hemodynamically. Hemodynamic compromise was easily
stabilized with fluid administration or vasopressor medications. Two pa-
tients with tumors extending to the right atrium required cardiopulmonary
bypass. The most common graft size diameter was 16 mm (range, 8-19
p
Cm). A right innominate vein to SVC graft was done in 18 patients (47%),
left innominate vein to SVC interposition graft in 8 (21%), grafts from the
roximal to distal SVC in 9 (24%), and the remaining 3 patients underwent
-type reconstructions. Graft diameters ranged from 8 to 16 mm when an
solated innominate vein SVC reconstruction was preformed and from 13 to
9 mm when the graft went from the proximal SVC to the distal SVC.
ollow-up averaged 15 months (range, 1-113 months), during which 11
atients (29%) died. At the last follow-up, all patients demonstrated minimal
o no brachiocephalic swelling. Imaging was performed after an average of
4 months (range, 1-113 months) in 20 patients (53%). Postoperative
nticoagulation consisted of aspirin only in all but 2 patients. In patients
ndergoing imaging, only 2 of the 20 demonstrated graft occlusion.
Comment: This series of SVC reconstructions primarily for malignant
isease has technical points worth noting. Warfarin anticoagulation is appar-
ntly not required. Graft occlusion is well tolerated. The authors detail
ethods to avoid graft kinking, particularly with sternotomy closure. Also,
econstruction of only one innominate vein when SVC innominate conflu-
nce is involved provides adequate results. It is technically more difficult to
erform a right innominate vein-to-graft anastomosis then a left innominate
ein anastomosis. However, the right anastomosis results in minimal graft
ngulation and direct blood flow into the right atrium. Sternal retractors
hould be partially closed before creating the second anastomosis in a left
nnominate to SVC reconstruction. Performing both anastomoses with
ternal distraction results in graft kinking with sternotomy closure.
chieving the Goal of the Fistula First Breakthrough Initiative for
revalent Maintenance Hemodialysis Patients
ynch JR, Wasse H, Armistead NC, et al. Am J Kidney Dis 2010;57:78-89.
Conclusions: Achieving the Center for Medicare and Medicaid Ser-
ices (CMS) goal of 66% prevalent arteriovenous fistula (AVF) use is feasible
or individual dialysis facilities. There is a need for decreased regional
ariation in fistula use to fully realize the CMS goal.
Summary: National Kidney Foundation Kidney Disease Outcome
uality Initiative (DOQI) guidelines recommend AVF at onset of hemodi-
lysis (Am J Kidney Dis 2006;48:S176-322). CMS then developed the
istula First Breakthrough Initiative (FFBI) to improve AVF use in the
nited States and collect data on fistula usage. The initial FFBI goal was 40%
revalence of AVFs. Once achieved, CMS established a new goal of 66%
VF use by June 2009. The target 66%was based on the fact AVF prevalence
n Asia and Europe is 60% to 90% (Ethier J, Nephrol Dial Transplant
008;23:3219-26). However, some point out that the end-stage renal
isease (ESRD) population in Asia and Europe may not be similar to that in
he United States. In addition, AVF usage in the United States is measured
or the entire ESRD population. International estimates can be based on
reatment facility samples and may not capture the entire ESRD population.
his led some to question the appropriateness of the 66% CMS goal of AVF
se.
The authors examined patterns of AVF use to assess the potential for
ttaining the CMS goal. This was an observational study involving U.S.
ialysis facilities with a mean patient census of 10 from January 2007 to
pril 2010. The authors tracked mean changes in facility level AVF use and
he percentage of facilities achieving the 66% CMS goal. The data were
erived from 4058 dialysis facilities with a mean patient census of 72  4.
ean prevalent AVF use increased from 45.3% to 55.5% (P  0.001), with
ubstantial variation across regions. During the 40 months of the study,
458 facilities (35.9%) reached the CMS goal at least once. Obtainment of
he goal varied from 22.1% of all treatment facilities in Network 5 (repre-
enting the mid-Atlantic states) to 79.0% in Network 16 (representing the
acific Northwest). The percentage of facilities achieving the goal increased
rom 6.4% to 19% during the 40 months (P .001). Facilities achieving the
MS goal sustained mean AVF use 66% of the time for 12.9  11.9
onths. The variation in proportion of facility patients using an AVF in the
ast measured month was only explained 20% of the time by case mix and
ther facility characteristics, indicating substantial unexplained variability in
se of AVFs.
Comment: The CMS goal of achieving 66% prevalent AVF use is
btainable, but not easily. AVF performances differ vastly in geographically
ontiguous networks. Facilities with higher percentages of white and His-
anic patients, patients with diabetes as a primary cause of ESRD, patients
ith glomerulonephritis as the primary cause of ESRD, and patients begin-
ing long-term hemodialysis therapy tended to have higher AVF use. AVF
se was lower in facilities with higher percentages of women, patients with
eripheral vascular disease starting hemodialysis, and with older populations.
ase mix, however, explains only a proportion of the variation of AVF use,
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